These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27438815)

  • 21. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.
    John A; Vetrivel U; Subramanian K; Deepa PR
    J Biomol Struct Dyn; 2017 May; 35(6):1350-1366. PubMed ID: 27145135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.
    Meirson T; Samson AO; Gil-Henn H
    Drug Des Devel Ther; 2017; 11():1535-1557. PubMed ID: 28572720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-Based Virtual Screening of Commercially Available Compound Libraries.
    Kireev D
    Methods Mol Biol; 2016; 1439():65-76. PubMed ID: 27316988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual fragment screening: exploration of MM-PBSA re-scoring.
    Kawatkar S; Moustakas D; Miller M; Joseph-McCarthy D
    J Comput Aided Mol Des; 2012 Aug; 26(8):921-34. PubMed ID: 22869295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
    Deniz U; Ozkirimli E; Ulgen KO
    J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beware of machine learning-based scoring functions-on the danger of developing black boxes.
    Gabel J; Desaphy J; Rognan D
    J Chem Inf Model; 2014 Oct; 54(10):2807-15. PubMed ID: 25207678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Power of Different Types of Experimental Restraints in Small Molecule Docking: A Review.
    Fu DY; Meiler J
    J Chem Inf Model; 2018 Feb; 58(2):225-233. PubMed ID: 29286651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors.
    Watt JE; Hughes GR; Walpole S; Monaco S; Stephenson GR; Bulman Page PC; Hemmings AM; Angulo J; Chantry A
    Chemistry; 2018 Dec; 24(67):17677-17680. PubMed ID: 30207403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study.
    Anusuya S; Velmurugan D; Gromiha MM
    J Biomol Struct Dyn; 2016 Jul; 34(7):1512-32. PubMed ID: 26262439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
    Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
    J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving docking results via reranking of ensembles of ligand poses in multiple X-ray protein conformations with MM-GBSA.
    Greenidge PA; Kramer C; Mozziconacci JC; Sherman W
    J Chem Inf Model; 2014 Oct; 54(10):2697-717. PubMed ID: 25266271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.
    Liu J; Gao J; Li F; Ma R; Wei Q; Wang A; Wu J; Ruan K
    Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3061-3070. PubMed ID: 27721047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
    Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
    J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.